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We genotyped 15 Bacillus anthracis isolates from Chad, Africa, using multiple-locus variable-number tandem repeat
analysis and three additional direct-repeat markers. We identified two unique genotypes that represent a novel genetic
lineage in the A cluster. Chadian isolates were susceptible to 11 antibiotics and free of 94 antibiotic resistance genes.
Bacillus anthracis, the etiological agent of anthrax, is a
sporulating bacterium causing disease primarily in herbivores
in many countries of Southern Europe, South America, Asia,
and Africa (22). In Chad, anthrax is hyperendemic in cattle
(22), and human cases of intestinal and cutaneous anthrax are
reported each year (World Anthrax Data Site [http://www
.vetmed.lsu.edu/whocc/]). However, studies of the genetic di-
versity and antibiotic susceptibilities of B. anthracis in this
country have not been conducted. Here, we used a previously
reported eight-marker multiple-locus variable-number tandem
repeat (VNTR) analysis (MLVA) method (13) and three ad-
ditional direct-repeat (DR) markers (15) to examine the ge-
netic diversity of this pathogen in Chad. We also evaluated the
Chadian B. anthracis isolates for antibiotic resistance by using
physiological and genetic methods.
Between 1996 and 2003, 174 blood samples were taken from
the heart region or jugular vein of cattle carcasses in five
southern prefectures in Chad. The samples were screened for
B. anthracis by cultivation on tryptone soy agar plates contain-
ing 5% sheep blood. After incubation at 37°C for 48 h, cultures
from 15 samples were identified as B. anthracis on the basis of
colony morphology, absence of hemolysis, and susceptibility to
B. anthracis-specific  phage (2, 21). These cultures were sent
to the Swiss Reference Centre (Bern, Switzerland) for further
physiological and genetic testing.
Template DNA for PCR was obtained by cell lysis followed
by filtration (18). PCRs were performed using Taq DNA poly-
merase (Roche Diagnostics, Basel, Switzerland) and an an-
nealing temperature of 55°C if not otherwise specified. We
used PCR to screen the samples for the presence of B. anthra-
cis chromosomal (Ba813) and plasmid (pXO1 and pXO2) se-
quences (see Table 1 for PCR targets and primer sequences).
Eight VNTR markers, vrrA, vrrB1, vrrB2, vrrC1, vrrC2, CG3,
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FIG. 1. Dendrogram based on MLVA of eight markers of Chadian
B. anthracis strains and the diverse 88 genotypes reported by Keim et
al. (13). The dendrogram was generated by clustering using the un-
weighted-pair group method with arithmetic means. Note that geno-
type 25 has been removed from the analysis since this strain no longer
possesses the pXO2 plasmid, resulting in missing data in the MLVA.
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pXO1-aaT, and pXO2-at, were amplified by PCR according to
the method of Keim et al. (13) and sequenced on an ABI Prism
3100 genetic analyzer (Applied Biosystems, Foster City, CA)
with dRhodamine-labeled terminators. The sizes of the VNTR
amplicons were compared to previously published allele sizes
(13, 20) as well as to the 11 B. anthracis strain genome se-
quences from GenBank (http://www.ncbi.nlm.nih.gov).
Since comparisons of the sequence sizes to the fragment size
data revealed minor size discrepancies (1 bp for vrrA, 3 bp for
vrrC1, and a previously reported 3-bp shift in the pXO1 size [P.
Keim, personal communication] [6]), MLVA-8 fragment anal-
ysis of 88 diverse genotypes (13) and two Chadian isolates
(isolate ChadA1, group VII, and isolate ChadA8, group VIII)
was performed in the Keim genetics laboratory (Northern Ar-
izona University) to ensure the comparability and accuracy of
the raw VNTR scores from the Chadian strains with reference
to those from the genotypes published by Keim et al. in 2000
(13) (Fig. 1).
Three additional DR regions of the B. anthracis chromo-
some (markers AJ03, AA03, and AT07) were amplified by
PCR as described previously (15), except that an annealing
temperature of 45°C was used. The sequences for the different
markers were compared to each other by multiple sequence
alignment with ClustalW (http://www.ch.embnet.org) and the
numbers of DRs determined (Table 2). The Sterne strain
NCTC8234 was used as a control, and the positions of the DRs
were matched to the complete nucleotide (nt) sequence of this
strain (GenBank accession no. AE017225). In the Sterne
strain, the AJ03 marker is characterized by a succession of two
40-bp DRs (1092652CGAT-32 nt-GCGC1092731), the AA03 by a
succession of three slightly imperfect repeats (1721256TTCA-
61/62/63 nt-TTAG1721502), and the AT07 marker by a succes-
sion of seven 39-bp DRs (4234463ACTA-31 nt-TGAT4234735).
FIG. 2. Geographical and genetic distribution of B. anthracis in the
different prefectures of Chad. Frequency of occurrence of B. anthracis
in the different prefectures is indicated by different gray patterns. The
numbers of strains isolated in the different town/village areas (■)
appear in parentheses after the respective names. The distribution of
the two different genotypic groups VII and VIII within the prefectures
is indicated in parentheses in the figure panel.
TABLE 1. List of the oligonucleotide primers used for B. anthracis strain identification and differentiation
Gene/locus Primer Oligonucleotide sequence (5 to 3) Reference
pag (pXO1) PA5 TCCTAACACTAACGAAGTCG 1, 22
PA8 GAGGTAGAAGGATATACGGT
capB
(pXO2)
1234 CTGAGCCATTAATCGATATG 12, 22
1301 TCCCACTTACGTAATCTGAG
Ba813 R1 TTAATTCACTTGCAACTGATGGG 17
R2 AACGATAGCTCCTACATTTGGAG
AA03 AA032 TTAGCGCCCCCTTGCGTTCC 15
AA033 TTAGCGCCCCTAGACCAATTGC
AJ03 AJ035 AGCACCTCGTTCATGCTCATAACGG 15
AJ036 AGCACCTCGTCTACTTCATTTTGTGC
AT07 AT073 CTCCTCAAATTACTAAAATGAAACC 15
AT074 TTGGCATAGACGTATATTGCGGTCC
vrrA vrrA-f1 CACAACTACCACCGATGGCACA 13
vrrA-r1 GCGCGTTTCGTTTGATTCATAC
vrrB1 vrrB1-f1 ATAGGTGGTTTTCCGCAAGTTATTC 13
vrrB1-r1 GATGAGTTTGATAAAGAATAGCCTGTG
vrrB2 vrrB2-f1 CACAGGCTATTCTTTATCAAACTCATC 13
vrrB2-r1 CCCAAGGTGAAGATTGTTGTTGA
vrrC1 vrrC1-f1 GAAGCAAGAAAGTGATGTAGTGGAC 13
vrrC1-r1 CATTTCCTCAAGTGCTACAGGTTC
vrrC2 vrrC2-f1 CCAGAAGAAGTGGAACCTGTAGCAC 13
vrrC2-r1 GTCTTTCCATTAATCGCGCTCTATC
CG3 CG3-f1 TGTCGTTTTACTTCTCTCTCCAATAC 13
CG3-r1 AGTCATTGTTCTGTATAAAGGGCAT
pXO1-aat pXO1-AAT-f3 CAATTTATTAACGATCAGATTAAGTTCA 13
pXO1-AAT-r3 TCTAGAATTAGTTGCTTCATAATGGC
pXO2-at pXO2-AT-f1 TCATCCTCTTTTAAGTCTTGGGT 13
pXO2-AT-r1 GTGTGATGAACTCCGACGACA
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The antibiotic susceptibilities of the Chadian B. anthracis
isolates were measured in Mu¨ller-Hinton broth by using cus-
tom Sensititre susceptibility plates (Trek Diagnostics Systems,
East-Grinstead, England, and MCS Diagnostics BV, JL Swal-
men, The Netherlands), according to the CLSI guidelines (7).
To exclude the possibility that Chadian B. anthracis isolates
possessed antibiotic resistance genes that were not phenotyp-
ically expressed in vitro, we screened for the presence of 94
gram-positive bacterial antibiotic resistance genes using a mi-
croarray (18).
PCR analysis revealed that the 15 isolates were B. anthracis
and positive for the pXO1 and pXO2 plasmids. The fragment
sizes and DNA sequences for the eight MLVA markers were
identical in all Chadian strains. The effective sizes and the
corrected, normalized scores for the eight MLVA alleles of the
Chadian strains are listed in Table 2. Of note, this is the first
report of a 133-bp allele in pXO2. Analysis by unweighted-pair
group method using average linkages clustered samples into a
new genetic group in the A branch according to Keim’s clas-
sification system (A) (Fig. 1) (13). We used the system pro-
posed by Levy et al. (15) to classify the 15 B. anthracis isolates
into two different, novel genotypic groups (VII and VIII) (Ta-
ble 2). These groups are new since this combination of DRs
within the three markers has yet to be reported for B. anthracis,
and the five-DR pattern in the AT07 marker in all Chadian
strains is unique. We found no obvious geographic clustering
of group VII and VIII strains (Fig. 2).
The Chadian isolates were susceptible to the antibiotics
tested but displayed decreased susceptibilities to ceftiofur,
erythromycin, and the combination quinupristin-dalfopristin
and a slightly higher MIC for clindamycin (MIC, 0.5 g/ml)
than the Sterne strain NCTC8234 (Table 2).
Microarray-based analysis revealed that the strains were free
of all antibiotic resistance genes tested except the -lactamase
genes bla1 and bla2, which are endogenous to B. anthracis but
are not expressed (5).
This study is the first to describe the genetic and physiolog-
ical attributes of B. anthracis strains in Chad. Certainly, this
region of Africa has been underrepresented in previous studies
of the global genetic diversity of B. anthracis (13). On a re-
gional level, the identical MLVA genotypes of the Chadian
strains indicate a high degree of genetic similarity among B.
anthracis isolates within the country. This is supported by the
existence of only two unique, closely related strains identified
by the three additional DR markers (groups VII and VIII) and
the absence of antibiotic resistance genes in all the tested
isolates. Similarly, our data suggest a low level of phenotypic
diversity as it relates to antibiotic resistance. The finding that
TABLE 2. Genetic diversity and antibiotic susceptibilities of B. anthracis strains from different regions in Chad
Strain(s)
Geographical origin Allele size (bp)
b for indicated
MVLA-8 marker
Town/village Prefecture (regiona) vrrA vrrB1 vrrB2 vrrC1 vrrC2 CG3 pXO1 pXO2
ChadA1 N’Djamena Chari Baguirmi (CW) 290 229 171 616 604 158 123 133
ChadA2 N’Djamena Chari Baguirmi (CW) 290 229 171 616 604 158 123 133
ChadA3 Massakory Chari Baguirmi (CW) 290 229 171 616 604 158 123 133
ChadA4 Dourbali Chari Baguirmi (CW) 290 229 171 616 604 158 123 133
ChadA5 Karal Chari Baguirmi (CW) 290 229 171 616 604 158 123 133
ChadA6 Am-Timan Salamat (CE) 290 229 171 616 604 158 123 133
ChadA7 Bongor Mayo Kebbi (SW) 290 229 171 616 604 158 123 133
ChadA8 Koumra Moyen-Chari (SE) 290 229 171 616 604 158 123 133
ChadA9 Massenya Chari Baguirmi (CW) 290 229 171 616 604 158 123 133
ChadA10 Bitkine Guera (C) 290 229 171 616 604 158 123 133
ChadA11 Mandelia Chari Baguirmi (CW) 290 229 171 616 604 158 123 133
ChadA12 Bongor Mayo Kebbi (SW) 290 229 171 616 604 158 123 133
ChadA13 Moıˆssala Moyen-Chari (SE) 290 229 171 616 604 158 123 133
ChadA14 Bongor Mayo Kebbi (SW) 290 229 171 616 604 158 123 133
ChadA15 Karal Chari Baguirmi (CW) 290 229 171 616 604 158 123 133
NCTC8234f 314 (313) 229 (229) 162 (162) 580 (583) 532 (532) 158 (158) 132 (129)
All Chadian strains (289) (229) (171) (613) (604) (158) (120) (133)
a C, central; CW, central west; CE, central east; SW, southwest; SE, southeast.
b Values in parentheses indicate allele sizes determined following correction and normalization. The sizes of the alleles are based on their effective lengths in base
pairs determined by sequence analysis, since discrepancies exist between the sizes determined by MLVA fragment analysis (14) and the real sizes of alleles vrrA (290
versus 289 bp for the Chadian strains and 314 versus 313 bp for the Sterne strain), vrrC1 (616 versus 613 bp for the Chadian strains and 580 versus 583 bp for the Sterne
strain), and pXO1 (123 versus 120 bp for the Chadian strains and 132 versus 129 bp for the Sterne strain).
c RAPD, random amplified polymorphic DNA.
d The groups are based on the numbers of DRs in markers AA03, AJ03, and AT07 according to the classification of Levy et al. (15); groups VII and VIII are new groups.
e MICs were determined in duplicate, and the MIC interpretive standards were those recommended in CLSI supplement M100-S15 (8). Antibiotics: GEN,
gentamicin; ERY, erythromycin; CLI, clindamycin, SYN, quinupristin-dalfopristin; TET, tetracycline; CHL, chloramphenicol; CIP, ciprofloxacin; XNL, ceftiofur; VAN,
vancomycin; PEN, penicillin; AMC, amoxicillin-clavulanic acid. The CLSI susceptibility breakpoints are as follows: for GEN, 4; for ERY, 0.5; for CLI, 0.5; for
SYN, 1; for TET, 1; for CHL, 8; for CIP, 0.5; for VAN, 4; for PEN, 0.12; for AMC, 4/2. The CLSI susceptibility breakpoints for TET, CIP, and PEN are
those recommended in CLSI supplement M100-S15 (8). For GEN, ERY, CLI, SYN, CHL, VAN, and AMC, S. aureus susceptibility breakpoints are suggested since
no susceptibility breakpoints were available for B. anthracis in the CLSI supplement (3, 4, 16). No CLSI criteria for susceptibility were available for XNL. The CLSI
resistance breakpoints are as follows: for GEN, 16; for ERY, 8; for CLI, 4; for SYN, 4; for CHL, 32; for VAN, 32; for PEN, 0.25; for AMC, 8/4. The
resistance breakpoint for PEN is that recommended in CLSI supplement M100-S15 (8). For GEN, ERY, CLI, SYN, CHL, VAN, and AMC, S. aureus resistance
breakpoints are suggested since no resistance breakpoints were available for B. anthracis in the CLSI supplement (3, 14, 16). No CLSI criteria for resistance were
available for TET, CIP, or XNL.
f The vaccine strain Sterne 34F2 (NCTC8234) was used as a control.
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Chadian isolates were susceptible to 11 antibiotics and free of
antibiotic resistance genes is significant from a public health
perspective and can be used for therapeutic measures in the
treatment of people affected with B. anthracis in this country.
From a global perspective, our MLVA and DR analysis
showed that the Chadian strains displayed unique genetic sig-
natures and are not closely related to any of the worldwide B.
anthracis strains analyzed to date (6, 9, 10, 11, 13, 19, 20).
Indeed, the long branch lengths of the A group indicate a
considerable degree of evolutionary divergence for these two
strains from the remaining B. anthracis isolates in the A lineage
(Fig. 1). In summary, our results provide a first look at the
genetic diversity and antibiotic resistance patterns of this
pathogen in Chad and can be useful for future epidemiological
analyses of anthrax outbreaks in this region.
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TABLE 2—Continued
Cluster
No. of DRs for indicated
RAPDc marker Groupd
Antibiotic MIC (g/ml)e
AA03 AJ03 AT07 GEN ERY CLI SYN TET CHL CIP XNL VAN PEN AMC
A 2 2 5 VII 1 1 0.5 2 1 4 0.25 8 2 0.12 2/1
A 2 2 5 VII 1 1 0.5 2 1 4 0.25 8 2 0.12 2/1
A 2 2 5 VII 1 1 0.5 1 1 4 0.25 8 2 0.12 2/1
A 2 2 5 VII 1 1 0.5 2 1 4 0.25 8 2 0.12 2/1
A 2 4 5 VIII 1 1 0.5 2 1 8 0.25 8 2 0.12 2/1
A 2 2 5 VII 1 1 0.5 2 1 4 0.25 8 2 0.12 2/1
A 2 4 5 VIII 1 1 0.5 1 1 8 0.25 8 2 0.12 2/1
A 2 4 5 VIII 1 1 0.5 1 1 8 0.25 8 2 0.12 2/1
A 2 2 5 VII 1 1 0.5 1 1 4 0.25 8 2 0.12 2/1
A 2 2 5 VII 1 0.5 0.5 1 1 4 0.25 8 2 0.12 2/1
A 2 2 5 VII 1 1 0.5 2 1 4 0.25 8 2 0.12 2/1
A 2 2 5 VII 1 1 0.5 1 1 4 0.25 8 2 0.12 2/1
A 2 2 5 VII 1 0.5 0.5 1 1 8 0.25 8 2 0.12 2/1
A 2 2 5 VII 1 1 0.5 1 1 8 0.25 8 2 0.12 2/1
A 2 2 5 VII 1 1 0.5 1 1 4 0.25 8 2 0.12 2/1
3 2 7 II 1 1 0.25 1 1 8 0.25 8 2 0.12 2/1
A
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